The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients

Clicks: 311
ID: 272428
2003
Free PDF
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
Systematically titrating bedtime basal insulin added to oral therapy can safely achieve 7% HbA(1c) in a majority of overweight patients with type 2 diabetes with HbA(1c) between 7.5 and 10.0% on oral agents alone. In doing this, glargine causes significantly less nocturnal hypoglycemia than NPH, thu …
Reference Key
mc2003diabetesthe Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Riddle MC;Rosenstock J;Gerich J; ;;
Journal Diabetes care
Year 2003
DOI
DOI not found
URL
http://www.ncbi.nlm.nih.gov/pubmed/14578243
Keywords
insulin Administration National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine treatment outcome research support non-u.s. gov't algorithms adult female male aged middle aged Clinical Trial Randomized Controlled Trial Multicenter Study Body Weight drug therapy combination diabetes mellitus oral blood glucose / drug effects insulin / administration & dosage* investigators=[] affs=[]) hypoglycemic agents / administration & dosage* pmid:14578243 doi:10.2337/diacare.26.11.3080 matthew c riddle julio rosenstock collabauthor(name='insulin glargine 4002 study investigators' type 2 / drug therapy* hypoglycemia / chemically induced hypoglycemic agents / adverse effects insulin / adverse effects insulin / analogs & derivatives* insulin glargine isophane / administration & dosage* isophane / adverse effects long-acting

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.